Raloxifene and Tamoxifen Interaction

Avoid
Researched 95% confidence

Raloxifene and Tamoxifen have a potentially harmful interaction with 95% confidence. Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery. Both compounds affect the gonads and pituitary, so monitoring these systems is recommended.

Compound Profiles

Raloxifene

Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health

Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity.

Half-life: ~28 hours Typical dose: 60mg oral daily pct
estrogen receptor hepatotoxicpct agentteratogenic
View full profile

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Half-life: ~5-7 days Typical dose: 20-40mg oral daily pct
cyp3a4estrogen receptor anticoagulantcarcinogenic riskhepatotoxicpct agent
View full profile

Combined Organ Load

Gonads
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Raloxifene, Tamoxifen). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the pct-agent safety flag (Raloxifene, Tamoxifen). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (Raloxifene, Tamoxifen). Monitor accordingly.

Frequently Asked Questions

Can I take Raloxifene with Tamoxifen?

Combining Raloxifene with Tamoxifen is not recommended. Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery.

Is Raloxifene and Tamoxifen safe together?

This combination carries significant risk. Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery. Consult a healthcare professional before combining.

What are the interactions between Raloxifene and Tamoxifen?

Both are SERMs that compete for the same estrogen receptors. Combining two SERMs provides no meaningful additive benefit for gynecomastia or PCT and increases the risk of side effects including thromboembolic events. Choose one SERM based on the clinical goal: raloxifene for gynecomastia, tamoxifen for HPTA recovery. This assessment has 95% confidence and is based on documented research data.

How should I time Raloxifene and Tamoxifen?

Raloxifene has a half-life of ~28 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Raloxifene vs Tamoxifen

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.